Scinai Immunotherapeutics (NASDAQ: SCNI) , a biopharma company focused on inflammation and immunology, announced that Dr. Roberta Lotti of Pincell Sr ...

CAR-T cells, which are genetically programmed to specifically recognize and kill target cells, have altered the therapeutic ...

This study aimed to repurpose the antifungal drug flucytosine (FCN) for anticancer activity together with cocrystals of nutraceutical coformers sinapic acid (SNP) and syringic acid (SYA). The ...

Tumour necrosis factor (TNF)-related apoptosis-inducing ligand (TRAIL) receptors (TRAILR1 and TRAILR2) are promising targets for cancer therapy: both recombinant TRAIL and monoclonal antibodies ...